Dynavax Technologies Corporation (DVAX)

NASDAQ: DVAX · IEX Real-Time Price · USD
12.17
-0.33 (-2.64%)
At close: Jun 28, 2022 4:00 PM
12.06
-0.11 (-0.90%)
After-hours: Jun 28, 2022 7:22 PM EDT
-2.64%
Market Cap 1.54B
Revenue (ttm) 470.10M
Net Income (ttm) 104.11M
Shares Out 126.31M
EPS (ttm) 0.75
PE Ratio 16.16
Forward PE 9.19
Dividend n/a
Ex-Dividend Date n/a
Volume 1,205,801
Open 12.53
Previous Close 12.50
Day's Range 12.02 - 12.71
52-Week Range 7.26 - 21.39
Beta 1.41
Analysts Buy
Price Target 26.27 (+115.9%)
Earnings Date Aug 3, 2022

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.... [Read more...]

Industry Biotechnology
IPO Date Feb 19, 2004
CEO Ryan Spencer
Employees 311
Stock Exchange NASDAQ
Ticker Symbol DVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is 26.27, which is an increase of 115.86% from the latest price.

Price Target
$26.27
(115.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster

SHANGHAI, China, June 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic...

Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

Other symbols: VALN

Why Dynavax Crushed the Market on Thursday

Its partner's coronavirus vaccine comes one important step closer to approval in Europe.

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in E...

Saint Herblain (France ), June 23 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

Other symbols: VALN

Valneva Announces Settlement Agreement with the UK Government

Saint- Herb lain (France ) , June 15 , 202 2 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Gove...

Other symbols: VALN

Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Pri...

-- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™  ( Sinovac Inactivated Vaccine ), Comirnaty ® ( Pfizer mRNA Vaccine ), and Va...

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

Saint-Herb lain (France ) , June 1 0 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provides an update on its European inactivated whole-virus COVID-19 vac...

Other symbols: VALN

4 Small Caps for Growth-Focused Investors

Investors seeking opportunities among growth stocks could be interested in the following small caps as they represent companies whose trailing 12-month net income per share has improved significantly on...

Other symbols: SFIXSTEMUUUU

Clover Provides Update on 2022 Corporate Milestones

-- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected to be ready for GMP inspections in Q3-2022 -- -- Regulatory submiss...

Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference

EMERYVILLE, Calif. , May 25, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today ...

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Why Dynavax Stock Blasted 16% Higher Today

One of its vaccine partners had some encouraging regulatory news to report.

Why Dynavax Stock Won on a Losing Monday for the Market

The company earns an Emergency Use Authorization from a well-off Middle Eastern country.

Dynavax to Present at the H.C. Wainwright Global Investment Conference

EMERYVILLE, Calif. , May 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today ...

Valneva Receives Notice of European Commission's Intent to Terminate COVID-19 Vaccine Purchase Agreement

Saint-Herb lain (France ) , May 16 , 2 02 2 – Valneva SE, a specialty vaccine company, today announced that it has received a notice from the European Commission (“EC”) of intent to terminate the advanc...

Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Reports First Quarter 2022 Financial Results

First quarter 2022 total revenue of $114.0 million, up 37% from $83.3 million for Q1 2021 HEPLISAV-B® vaccine net product revenue of $20.8 million, up 151% from $8.3 million for Q1 2021 CpG 1018® adjuva...

Clover's Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of ...

-- Bivalent candidate (Prototype + Omicron) demonstrates broad neutralization against Omicron and all VoCs in both primary vaccination and booster settings in preclinical study -- -- Potential to pursue...

Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine Candidate

Saint-Herb lain (France) , May 4, 2 02 2 – Valneva SE, a specialty vaccine company, today announced the initiation of a heterologous booster trial of its inactivated whole-virus COVID-19 vaccine candida...

Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

EMERYVILLE, Calif. , April 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vac...

Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease

--94% cumulative protective effect against COVID-19 in previously-infected individuals that subsequently received Clover's COVID-19 vaccine candidate-- --First and only COVID-19 vaccine candidate to dem...

Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washingt...

SHANGHAI, China, April 19, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeuti...

Clover To Present at World Vaccine Congress Washington 2022

SHANGHAI, China, April 12, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeuti...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif. , April 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 28,250 shares...

Clover Reports Full Year 2021 Financial Results

SHANGHAI, China, March 29, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeuti...